Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

744 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K; Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG). Ogura M, et al. Among authors: kurosawa m. Cancer Sci. 2018 Sep;109(9):2830-2840. doi: 10.1111/cas.13719. Epub 2018 Jul 28. Cancer Sci. 2018. PMID: 29957865 Free PMC article. Clinical Trial.
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.
Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, Ogura M, Hirano M, Asaoku H, Kurosawa M, Maeda Y, Omachi K, Moriuchi Y, Kasai M, Ohnishi K, Takayama N, Morishima Y, Tobinai K, Kaba H, Yamamoto S, Fukuda H, Kikuchi M, Yoshino T, Matsuno Y, Hotta T, Shimoyama M. Itoh K, et al. Among authors: kurosawa m. Int J Hematol. 2010 Apr;91(3):446-55. doi: 10.1007/s12185-010-0533-9. Epub 2010 Mar 3. Int J Hematol. 2010. PMID: 20198461
Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.
Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M. Watanabe T, et al. Among authors: kurosawa m. Leuk Lymphoma. 2010 May;51(5):813-21. doi: 10.3109/10428191003721359. Leuk Lymphoma. 2010. PMID: 20367565
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; TARGET Investigators. Tauchi T, et al. Leuk Res. 2011 May;35(5):585-90. doi: 10.1016/j.leukres.2010.10.027. Epub 2010 Dec 10. Leuk Res. 2011. PMID: 21145591
Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, Kinoshita T, Uike N, Ogura M, Nawano S, Mori S, Ohashi Y; IDEC-C2B8 Study Group. Tobinai K, et al. Among authors: kurosawa m. Cancer Sci. 2011 Sep;102(9):1698-705. doi: 10.1111/j.1349-7006.2011.02001.x. Epub 2011 Jul 8. Cancer Sci. 2011. PMID: 21645173 Free article. Clinical Trial.
Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
Azuma T, Tobinai K, Takeyama K, Shibata T, Hidaka M, Kurosawa M, Kasai M, Chou T, Fukushima N, Mukai K, Tsukasaki K, Shimoyama M; Japan Clinical Oncology Group-Lymphoma Study Group (JCOG-LSG), Tokyo, Japan. Azuma T, et al. Among authors: kurosawa m. Jpn J Clin Oncol. 2012 May;42(5):394-404. doi: 10.1093/jjco/hys029. Epub 2012 Mar 15. Jpn J Clin Oncol. 2012. PMID: 22422899 Clinical Trial.
Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A).
Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, Tomoyose T, Uozumi K, Kobayashi Y, Fukushima N, Utsunomiya A, Tara M, Nosaka K, Hidaka M, Uike N, Yoshida S, Tamura K, Ishitsuka K, Kurosawa M, Nakata M, Fukuda H, Hotta T, Tobinai K, Tsukasaki K. Fukushima T, et al. Among authors: kurosawa m. Br J Haematol. 2014 Sep;166(5):739-48. doi: 10.1111/bjh.12962. Epub 2014 Jun 14. Br J Haematol. 2014. PMID: 24931507 Free article.
Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
Shiratori S, Kosugi-Kanaya M, Shigematsu A, Kobayashi H, Yamamoto S, Kobayashi N, Iwasaki H, Mori A, Kunieda Y, Yutaka T, Kurosawa M, Kakinoki Y, Endo T, Kondo T, Hashino S, Teshima T; North Japan Hematology Study Group (NJHSG). Shiratori S, et al. Among authors: kurosawa m. Leuk Lymphoma. 2015;56(9):2592-7. doi: 10.3109/10428194.2014.1001985. Epub 2015 Feb 24. Leuk Lymphoma. 2015. PMID: 25563559
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators. Robak T, et al. N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096. N Engl J Med. 2015. PMID: 25738670 Free article. Clinical Trial.
744 results